# Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

> **NCT04090034** · — · RECRUITING · sponsor: **Methodist Health System** · enrollment: 50 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Gastroenteropancreatic Neuroendocrine Tumor

## Interventions

- **PROCEDURE:** Peptide Receptor Radionuclide Therapy

## Key facts

- **NCT ID:** NCT04090034
- **Lead sponsor:** Methodist Health System
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-28
- **Primary completion:** 2026-06-28
- **Final completion:** 2026-06-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090034, "Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04090034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*